Related Experiment Videos
Intravenous biperiden in akathisia: an open pilot study.
International Journal of Psychiatry in Medicine
|September 23, 2000
Summary
Intravenous biperiden rapidly and effectively treats antipsychotic-induced akathisia. This intravenous (IV) administration offers a faster onset and maximal effect compared to intramuscular (IM) injections, providing significant relief for patients.
Area of Science:
- Pharmacology
- Clinical Neuroscience
- Psychiatry
Background:
- Antipsychotic-induced akathisia is a severe side effect causing significant patient distress.
- Intramuscular biperiden is an established treatment, but faster relief may be possible.
- Investigating intravenous biperiden offers a potential for more rapid symptom amelioration.
Observation:
- A clinical trial compared intravenous (IV) and intramuscular (IM) biperiden in schizophrenia patients with acute akathisia.
- Seventeen patients received IV biperiden (5 mg), and six received IM biperiden (5 mg).
- The Barnes Akathisia Rating Scale assessed treatment efficacy.
Findings:
- Intravenous biperiden showed a mean onset of 1.6 minutes and maximal effect in 9.2 minutes.
- Intramuscular biperiden had a mean onset of 30.5 minutes and maximal effect in 50 minutes.
- Akathisia was completely resolved in all patients receiving IV biperiden, with mild, transient side effects.
Implications:
- Intravenous biperiden provides a significantly faster therapeutic effect than intramuscular administration.
- This route offers a promising, rapid, and effective treatment option for severe antipsychotic-induced akathisia.
- Further research may confirm IV biperiden as a first-line intervention for acute akathisia management.